Literature DB >> 29496517

Parallels between hematopoietic stem cell and prostate cancer disseminated tumor cell regulation.

Frank C Cackowski1, Russell S Taichman2.   

Abstract

The bone marrow is the primary site of hematopoiesis and the home for hematopoietic stem cells (HSCs) in adult mammals. Prostate cancer commonly metastasizes to the bone and forms bone metastases in almost all patients who die of the disease. Prostate cancer bone metastases are thought to develop after rare bone marrow disseminated tumor cells (DTCs) escape a dormant state and reactivate. Prostate cancer DTCs and normal HSCs have been shown to compete for residence in the bone marrow and share many of same regulatory mechanisms for survival, proliferation and homing. In this review, we highlight these parallels in order to help our readers use the literature in HSC and DTC biology to inform their research and generate hypotheses in both fields.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CXCL12; Disseminated tumor cell; Dormancy; GAS6; Hematopoietic stem cell; Niche; Prostate cancer; Recurrence; Stem cell

Mesh:

Year:  2018        PMID: 29496517      PMCID: PMC6109615          DOI: 10.1016/j.bone.2018.02.025

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  69 in total

1.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.

Authors:  L Bubendorf; A Schöpfer; U Wagner; G Sauter; H Moch; N Willi; T C Gasser; M J Mihatsch
Journal:  Hum Pathol       Date:  2000-05       Impact factor: 3.466

Review 2.  Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells?

Authors:  Aparna C Ranganathan; Alejandro P Adam; Lin Zhang; Julio A Aguirre-Ghiso
Journal:  Cancer Biol Ther       Date:  2006-07-01       Impact factor: 4.742

Review 3.  Innate and acquired immune surveillance in the postdissemination phase of metastasis.

Authors:  Hugo Gonzalez; Isabella Robles; Zena Werb
Journal:  FEBS J       Date:  2017-11-24       Impact factor: 5.542

Review 4.  The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?

Authors:  Vicki Plaks; Niwen Kong; Zena Werb
Journal:  Cell Stem Cell       Date:  2015-03-05       Impact factor: 24.633

5.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

6.  Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression.

Authors:  P Kloen; M C Gebhardt; A Perez-Atayde; A E Rosenberg; D S Springfield; L I Gold; H J Mankin
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

Review 7.  Stromal factors involved in prostate carcinoma metastasis to bone.

Authors:  Carlton R Cooper; Christopher H Chay; James D Gendernalik; Hyung-Lae Lee; Jasmine Bhatia; Russell S Taichman; Laurie K McCauley; Evan T Keller; Kenneth J Pienta
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

8.  Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow.

Authors:  Kenji Yumoto; Matthew R Eber; Jingcheng Wang; Frank C Cackowski; Ann M Decker; Eunsohl Lee; Ana Rita Nobre; Julio A Aguirre-Ghiso; Younghun Jung; Russell S Taichman
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

9.  GAS6 receptor status is associated with dormancy and bone metastatic tumor formation.

Authors:  Russell S Taichman; Lalit R Patel; Rachel Bedenis; Jingcheng Wang; Savannah Weidner; Taibriana Schumann; Kenji Yumoto; Janice E Berry; Yusuke Shiozawa; Kenneth J Pienta
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

10.  Differential expression of matrix metalloproteinase-2 expression in disseminated tumor cells and micrometastasis in bone marrow of patients with nonmetastatic and metastatic prostate cancer: theoretical considerations and clinical implications-an immunocytochemical study.

Authors:  Nigel P Murray; Eduardo Reyes; Pablo Tapia; Leonardo Badínez; Nelson Orellana
Journal:  Bone Marrow Res       Date:  2012-11-26
View more
  7 in total

1.  Primary hyperparathyroidism in prostate cancer: guilty or not guilty?

Authors:  G Mazziotti; S Frara; A Mosca
Journal:  Endocrine       Date:  2018-05-30       Impact factor: 3.633

2.  Magmas Inhibition in Prostate Cancer: A Novel Target for Treatment-Resistant Disease.

Authors:  Jianhui Yang; Bhaskar C Das; Omar Aljitawi; Avinash Kumar; Sasmita Das; Peter Van Veldhuizen
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

3.  Dosimetric Analysis of the Short-Ranged Particle Emitter 161Tb for Radionuclide Therapy of Metastatic Prostate Cancer.

Authors:  Peter Bernhardt; Johanna Svensson; Jens Hemmingsson; Nicholas P van der Meulen; Jan Rijn Zeevaart; Mark W Konijnenberg; Cristina Müller; Jon Kindblom
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

4.  Abscisic acid regulates dormancy of prostate cancer disseminated tumor cells in the bone marrow.

Authors:  Younghun Jung; Frank C Cackowski; Kenji Yumoto; Ann M Decker; Yu Wang; Megan Hotchkin; Eunsohl Lee; Laura Buttitta; Russell S Taichman
Journal:  Neoplasia       Date:  2020-12-06       Impact factor: 5.715

Review 5.  Stromal Co-Cultivation for Modeling Breast Cancer Dormancy in the Bone Marrow.

Authors:  Robert Wieder
Journal:  Cancers (Basel)       Date:  2022-07-09       Impact factor: 6.575

Review 6.  The current paradigm and challenges ahead for the dormancy of disseminated tumor cells.

Authors:  Emma Risson; Ana Rita Nobre; Veronique Maguer-Satta; Julio A Aguirre-Ghiso
Journal:  Nat Cancer       Date:  2020-07-06

Review 7.  Emerging and Established Models of Bone Metastasis.

Authors:  Alexander H Jinnah; Benjamin C Zacks; Chukwuweike U Gwam; Bethany A Kerr
Journal:  Cancers (Basel)       Date:  2018-06-01       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.